|
1
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gunderson LL, Jessup JM, Sargent DJ,
Greene FL and Stewart AK: Revised TN categorization for colon
cancer based on national survival outcomes data. J Clin Oncol.
28:264–271. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee JJ and Chu E: Adjuvant chemotherapy
for stage II colon cancer: The debate goes on. J Oncol Pract.
13:245–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knapen DG, Cherny NI, Zygoura P, Latino
NJ, Douillard JY, Dafni U, de Vries EGE and de Groot DJ: Lessons
learnt from scoring adjuvant colon cancer trials and meta-analyses
using the ESMO-magnitude of clinical benefit scale V.1.1. ESMO
Open. 5:e0006812020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varghese A: Chemotherapy for stage II
colon cancer. Clin Colon Rectal Surg. 28:256–261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolff RK, Hoffman MD, Wolff EC, Herrick
JS, Sakoda LC, Samowitz WS and Slattery ML: Mutation analysis of
adenomas and carcinomas of the colon: Early and late drivers. Genes
Chromosomes Cancer. 57:366–376. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
D'Orazi G, Cecchinelli B, Bruno T, Manni
I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal
G, et al: Homeodomain-interacting protein kinase-2 phosphorylates
p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 4:11–19. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hofmann TG, Möller A, Sirma H, Zentgraf H,
Taya Y, Dröge W, Will H and Schmitz ML: Regulation of p53 activity
by its interaction with homeodomain-interacting protein kinase-2.
Nat Cell Biol. 4:1–10. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Puca R, Nardinocchi L, Givol D and D'Orazi
G: Regulation of p53 activity by HIPK2: Molecular mechanisms and
therapeutical implications in human cancer cells. Oncogene.
29:4378–4387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blaquiere JA and Verheyen EM:
Homeodomain-interacting protein kinases: Diverse and complex roles
in development and disease. Curr Top Dev Biol. 123:73–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nardinocchi L, Puca R, Givol D and D'Orazi
G: HIPK2-a therapeutical target to be (re)activated for tumor
suppression: Role in p53 activation and HIF-1α inhibition. Cell
Cycle. 9:1270–1275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Orazi G, Rinaldo C and Soddu S: Updates
on HIPK2: A resourceful oncosuppressor for clearing cancer. J Exp
Clin Cancer Res. 31:632012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hofmann TG, Glas C and Bitomsky N: HIPK2:
A tumour suppressor that controls DNA damage-induced cell fate and
cytokinesis. Bioessays. 35:55–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuwano Y, Nishida K, Akaike Y, Kurokawa K,
Nishikawa T, Masuda K and Rokutan K: Homeodomain-interacting
protein kinase-2: A critical regulator of the DNA damage response
and the epigenome. Int J Mol Sci. 17:16382016. View Article : Google Scholar
|
|
16
|
Lavra L, Rinaldo C, Ulivieri A, Luciani E,
Fidanza P, Giacomelli L, Bellotti C, Ricci A, Trovato M, Soddu S,
et al: The loss of the p53 activator HIPK2 is responsible for
galectin-3 overexpression in well differentiated thyroid
carcinomas. PLoS One. 6:e206652011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nodale C, Sheffer M, Jacob-Hirsch J,
Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D and
D'Orazi G: HIPK2 downregulates vimentin and inhibits breast cancer
cell invasion. Cancer Biol Ther. 13:198–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan M, Gong H, Zeng Y, Tao L, Wang J,
Jiang J, Xu D, Bao E, Qiu J and Liu Z: Downregulation of
homeodomain-interacting protein kinase-2 contributes to bladder
cancer metastasis by regulating Wnt signaling. J Cell Biochem.
115:1762–1767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Wen P, Li F, Yao C, Wang T, Liang
B, Yang Q, Ma L and He L: HIPK2 inhibits cell metastasis and
improves chemosensitivity in esophageal squamous cell carcinoma.
Exp Ther Med. 15:1113–1118. 2018.PubMed/NCBI
|
|
20
|
Chen P, Duan X, Li X, Li J, Ba Q and Wang
H: HIPK2 suppresses tumor growth and progression of hepatocellular
carcinoma through promoting the degradation of HIF-1α. Oncogene.
39:2863–2876. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
D'Orazi G, Sciulli MG, Di Stefano V,
Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A and
Patrignani P: Homeodomain-interacting protein kinase-2 restrains
cytosolic phospholipase A2-dependent prostaglandin E2 generation in
human colorectal cancer cells. Clin Cancer Res. 12:735–741. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nardinocchi L, Puca R, Sacchi A and
D'Orazi G: Inhibition of HIF-1alpha activity by
homeodomain-interacting protein kinase-2 correlates with
sensitization of chemoresistant cells to undergo apoptosis. Mol
Cancer. 8:12009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin J, Zhang Q, Lu Y, Xue W, Xu Y, Zhu Y
and Hu X: Downregulation of HIPK2 increases resistance of bladder
cancer cell to cisplatin by regulating Wip1. PLoS One.
9:e984182014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Beiti MA and Lu X: Expression of HIPK2
in cervical cancer: Correlation with clinicopathology and
prognosis. Aust N Z J Obstet Gynaecol. 48:329–336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry
A, Leonard JR, Watson MA, Gutmann DH and Nagarajan R:
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2
amplification and increased expression in pilocytic astrocytomas.
Oncogene. 27:4745–4751. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng Y, Al-Beiti MA, Wang J, Wei G, Li J,
Liang S and Lu X: Correlation between homeodomain-interacting
protein kinase 2 and apoptosis in cervical cancer. Mol Med Rep.
5:1251–1255. 2012.PubMed/NCBI
|
|
27
|
Imberg-Kazdan K, Ha S, Greenfield A,
Poultney CS, Bonneau R, Logan SK and Garabedian MJ: A genome-wide
RNA interference screen identifies new regulators of androgen
receptor function in prostate cancer cells. Genome Res. 23:581–591.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de la Vega L, Grishina I, Moreno R, Krüger
M, Braun T and Schmitz ML: A redox-regulated SUMO/acetylation
switch of HIPK2 controls the survival threshold to oxidative
stress. Mol Cell. 46:472–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Torrente L, Sanchez C, Moreno R, Chowdhry
S, Cabello P, Isono K, Koseki H, Honda T, Hayes JD, Dinkova-Kostova
AT and de la Vega L: Crosstalk between NRF2 and HIPK2 shapes
cytoprotective responses. Oncogene. 36:6204–6212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garufi A, Traversi G, Gilardini Montani
MS, D'Orazi V, Pistritto G, Cirone M and D'Orazi G: Reduced
chemotherapeutic sensitivity in high glucose condition: Implication
of antioxidant response. Oncotarget. 10:4691–1702. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garufi A, Baldari S, Pettinari R,
Gilardini Montani MS, D'Orazi V, Pistritto G, Crispini A, Giorno E,
Toietta G, Marchetti F, et al: A ruthenium(II)-curcumin compound
modulates NRF2 expression balancing the cancer cell death/survival
outcome according to p53 status. J Exp Clin Cancer Res. 39:1222020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Orazi G, Garufi A and Cirone M: Nuclear
factor erythroid 2 (NF-E2) p45-related factor 2 interferes with
homeodomain-interacting protein kinase 2/p53 activity to impair
solid tumors chemosensitivity. IUBMB Life. 72:1634–1639. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vomund S, Schäfer A, Parnham MJ, Brüne B
and von Knethen A: Nrf2, the master regulator of anti-oxidative
responses. Int J Mol Sci. 18:27722017. View Article : Google Scholar
|
|
34
|
Wu S, Lu H and Bai Y: Nrf2 in cancers: A
double-edged sword. Cancer Med. 8:2252–2267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li CQ, Kim MY, Godoy LC, Thiantanawat A,
Trudel LJ and Wogan GN: Nitric oxide activation of Keap1/Nrf2
signaling in human colon carcinoma cells. Proc Natl Acad Sci USA.
106:14547–14551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu T, Yao Y, Yu S, Guo H, Han L, Wang W,
Tian T, Hao Y, Liu Z, Nan K and Wang S: Clinicopathologic
significance of CXCR4 and Nrf2 in colorectal cancer. J Biomed Res.
27:283–290. 2013.PubMed/NCBI
|
|
37
|
Lee YJ, Kim WI, Bae JH, Cho MK, Lee SH,
Nam HS, Choi IH and Cho SW: Overexpression of Nrf2 promotes colon
cancer progression via ERK and AKT signaling pathways. Ann Surg
Treat Res. 98:159–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Q, Deng H, Xia H, Xu M, Pan G, Mao J,
Tao S, Yamanaka K and An Y: High NF-E2-related factor 2 expression
predicts poor prognosis in patients with lung cancer: A
meta-analysis of cohort studies. Free Radic Res. Jul 24–2019.(Epub
ahead of print). doi: 10.1080/10715762.2019.1642472. View Article : Google Scholar
|
|
39
|
Wang YY, Chen J, Liu XM, Zhao R and Zhe H:
Nrf2-mediated metabolic reprogramming in cancer. Oxid Med Cell
Longev. 2018:93040912018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bawm S, Matsuura H, Elkhateeb A, Nabeta K,
Subeki, Nonaka N, Oku Y and Katakura K: In vitro antitrypanosomal
activities of quassinoid compounds from the fruits of a medicinal
plant, Brucea javanica. Vet Parasitol. 158:288–294. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao M, Lau ST, Leung PS, Che CT and Lin
ZX: Seven quassinoids from fructus bruceae with cytotoxic effects
on pancreatic adenocarcinoma cell lines. Phytother Res.
25:1796–1800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Panieri E, Buha A, Telkoparan-Akillilar P,
Cevik D, Kouretas D, Veskoukis A, Skaperda Z, Tsatsakis A, Wallace
D, Suzen S and Saso L: Potential applications of NRF2 modulators in
cancer therapy. Antioxidants (Basel). 9:1932020. View Article : Google Scholar
|
|
43
|
Ren D, Villeneuve NF, Jiang T, Wu T, Lau
A, Toppin HA and Zhang DD: Brusatol enhances the efficacy of
chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Proc Natl Acad Sci USA. 108:1433–1438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai SJ, Liu Y, Han S and Yang C: Brusatol,
an NRF2 inhibitor for future cancer therapeutic. Cell Biosci.
9:452019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. Springer; New York,
NY: pp. 252–254. 2017, PubMed/NCBI
|
|
46
|
de la Vega L, Hornung J, Kremmer E,
Milanovic M and Schmitz ML: Homeodomain-interacting protein kinase
2-dependent repression of myogenic differentiation is relieved by
its caspase-mediated cleavage. Nucleic Acids Res. 41:5731–5745.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ritter O and Schmitz ML: Differential
intracellular localization and dynamic nucleocytoplasmic shuttling
of homeodomain-interacting protein kinase family members. Biochim
Biophys Acta Mol Cell Res. 1866:1676–1686. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Manic G, Signore M, Sistigu A, Russo G,
Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Amoreo CA,
et al: CHK1-targeted therapy to deplete DNA replication-stressed,
p53-deficient, hyperdiploid colorectal cancer stem cells. Gut.
67:903–917. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Altschul SF, Gish W, Miller W, Myers EW
and Lipman DJ: Basic local alignment search tool. J Mol Biol.
215:403–410. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Contadini C, Monteonofrio L, Virdia I,
Prodosmo A, Valente D, Chessa L, Musio A, Fava LL, Rinaldo C, Di
Rocco G and Soddu S: p53 mitotic centrosome localization preserves
centrosome integrity and works as sensor for the mitotic
surveillance pathway. Cell Death Dis. 10:8502019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hothorn T and Lausen B: On the exact
distribution of maximally selected rank statistics. Comput Stat
Data Anal. 43:121–137. 2003. View Article : Google Scholar
|
|
53
|
Zhou L, Feng Y, Jin Y, Liu X, Sui H, Chai
N, Chen X, Liu N, Ji Q, Wang Y and Li Q: Verbascoside promotes
apoptosis by regulating HIPK2-p53 signaling in human colorectal
cancer. BMC Cancer. 14:7472014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kukcinaviciute E, Jonusiene V,
Sasnauskiene A, Dabkeviciene D, Eidenaite E and Laurinavicius A:
Significance of Notch and Wnt signaling for chemoresistance of
colorectal cancer cells HCT116. J Cell Biochem. 119:5913–5920.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sadeghi MR, Jeddi F, Soozangar N, Somi MH
and Samadi N: The role of Nrf2-Keap1 axis in colorectal cancer,
progression, and chemoresistance. Tumour Biol.
39:10104283177055102017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rojo de la Vega M, Chapman E and Zhang DD:
NRF2 and the hallmarks of cancer. Cancer Cell. 34:21–43. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Feng Y, Zhou L, Sun X and Li Q:
Homeodomain-interacting protein kinase 2 (HIPK2): A promising
target for anti-cancer therapies. Oncotarget. 8:20452–20461. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Calzado MA, Renner F, Roscic A and Schmitz
ML: HIPK2: A versatile switchboard regulating the transcription
machinery and cell death. Cell Cycle. 6:139–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huang Y, Liu N, Liu J, Liu Y, Zhang C,
Long S, Luo G, Zhang L and Zhang Y: Mutant p53 drives cancer
chemotherapy resistance due to loss of function on activating
transcription of PUMA. Cell Cycle. 18:3442–3455. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
No JH, Kim YB and Song YS: Targeting nrf2
signaling to combat chemoresistance. J Cancer Prev. 19:111–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Evans JP, Winiarski BK, Sutton PA, Jones
RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL,
Tweedle EM, et al: The Nrf2 inhibitor brusatol is a potent
antitumour agent in an orthotopic mouse model of colorectal cancer.
Oncotarget. 9:27104–27116. 2018. View Article : Google Scholar : PubMed/NCBI
|
